Cargando…
Treatment algorithm in patients with ovarian cancer
Most ovarian cancer patients are diagnosed only at advanced stages when survival outcomes are worse, andwhen therapeutic decisions might prove challenging. The fundamental treatment for women with ovarian cancerincludes debulking surgery whenever possible and appropriate systemic therapy (chemothera...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Universa Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7580261/ https://www.ncbi.nlm.nih.gov/pubmed/33123697 |
_version_ | 1783598752968212480 |
---|---|
author | Vergote, I Denys, H De Greve, J Gennigens, C Van De Vijver, K Kerger, J Vuylsteke, P Baurain, JF |
author_facet | Vergote, I Denys, H De Greve, J Gennigens, C Van De Vijver, K Kerger, J Vuylsteke, P Baurain, JF |
author_sort | Vergote, I |
collection | PubMed |
description | Most ovarian cancer patients are diagnosed only at advanced stages when survival outcomes are worse, andwhen therapeutic decisions might prove challenging. The fundamental treatment for women with ovarian cancerincludes debulking surgery whenever possible and appropriate systemic therapy (chemotherapy, targeted andantiangiogenic agents). In the last few years, knowledge about histological and molecular characteristics of ovariancancer subtypes and stages has increased considerably. This has enabled the development and improvement ofseveral options for the diagnosis and treatment of ovarian cancer in a patient-tailored approach. Accordingly,therapeutic decisions are guided by the characteristics of the patient and the tumour, especially the molecularfeatures of the cancer subtype and disease stage. Particularly relevant are the advances in early genetic testing ofgermline and somatic mutations involved in DNA repair, and the clinical development of targeted agents. In orderto implement the best individual medical strategies, in this article, we present an algorithm of treatment options,including recently developed targeted agents, for primary and recurrent ovarian cancer patients in Belgium. |
format | Online Article Text |
id | pubmed-7580261 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Universa Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-75802612020-10-28 Treatment algorithm in patients with ovarian cancer Vergote, I Denys, H De Greve, J Gennigens, C Van De Vijver, K Kerger, J Vuylsteke, P Baurain, JF Facts Views Vis Obgyn Viewpoint Paper Most ovarian cancer patients are diagnosed only at advanced stages when survival outcomes are worse, andwhen therapeutic decisions might prove challenging. The fundamental treatment for women with ovarian cancerincludes debulking surgery whenever possible and appropriate systemic therapy (chemotherapy, targeted andantiangiogenic agents). In the last few years, knowledge about histological and molecular characteristics of ovariancancer subtypes and stages has increased considerably. This has enabled the development and improvement ofseveral options for the diagnosis and treatment of ovarian cancer in a patient-tailored approach. Accordingly,therapeutic decisions are guided by the characteristics of the patient and the tumour, especially the molecularfeatures of the cancer subtype and disease stage. Particularly relevant are the advances in early genetic testing ofgermline and somatic mutations involved in DNA repair, and the clinical development of targeted agents. In orderto implement the best individual medical strategies, in this article, we present an algorithm of treatment options,including recently developed targeted agents, for primary and recurrent ovarian cancer patients in Belgium. Universa Press 2020-10-08 /pmc/articles/PMC7580261/ /pubmed/33123697 Text en Copyright © 2020 Facts, Views & Vision http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Viewpoint Paper Vergote, I Denys, H De Greve, J Gennigens, C Van De Vijver, K Kerger, J Vuylsteke, P Baurain, JF Treatment algorithm in patients with ovarian cancer |
title | Treatment algorithm in patients with ovarian cancer |
title_full | Treatment algorithm in patients with ovarian cancer |
title_fullStr | Treatment algorithm in patients with ovarian cancer |
title_full_unstemmed | Treatment algorithm in patients with ovarian cancer |
title_short | Treatment algorithm in patients with ovarian cancer |
title_sort | treatment algorithm in patients with ovarian cancer |
topic | Viewpoint Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7580261/ https://www.ncbi.nlm.nih.gov/pubmed/33123697 |
work_keys_str_mv | AT vergotei treatmentalgorithminpatientswithovariancancer AT denysh treatmentalgorithminpatientswithovariancancer AT degrevej treatmentalgorithminpatientswithovariancancer AT gennigensc treatmentalgorithminpatientswithovariancancer AT vandevijverk treatmentalgorithminpatientswithovariancancer AT kergerj treatmentalgorithminpatientswithovariancancer AT vuylstekep treatmentalgorithminpatientswithovariancancer AT baurainjf treatmentalgorithminpatientswithovariancancer |